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Background: Omega-3 index [erythrocyte eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA)] is a modifiable risk factor for 
cardiovascular death (greatest protection with an index of ≥ 8%) that can be improved with fish oil intake. Fish oil decreases mortality in cardiac 
patients, and, in high doses, lowers serum triglycerides (TGs) and modestly raises LDL-Cholesterol (C). The extent to which the benefits of a higher 
index are mediated by its association with lipid or inflammatory markers is unknown.
Methods: Omega-3 index was measured in 1074 patients enrolled in a prospective myocardial infarction (MI) registry (TRIUMPH), along with 
the comprehensive lipid panel (Atherotech, Birmingham AL) and hs-CRP (Roche Diagnostics, Indianapolis IN). The associations between the index 
and lipid and inflammatory markers were assessed after multivariable adjustment for age, gender, race, diabetes, hypertension, body mass index, 
smoking, kidney disease, heart failure, activity, and medications, including statins.
Results: Before adjustment, a modest inverse correlation was noted between omega-3 index, as a continuous variable, and total-C/HDL-C ratio (r=-
0.16, p=<.0001), LDL-C (r=-0.11, p= 0.0003), LDL-3 subfraction (r=-0.11, p= 0.0005), VLDL-C (r= -0.11, p=0.0006), and TGs (r=-0.11, p=0.0002). 
No correlation was noted with other LDL-C subfractions, HDL-C, HDL-C subfractions, hs-CRP (r=0.016, p=0.6, n=1121) or lipoprotein (a) (r=0.01, 
p= 0.7). In the fully adjusted model, less than 11% of the variability in omega-3 index could be explained by any single lipid parameter tested. [r2 
ranged from 0.103-0.108 for total-C/HDL-C ratio (p=0.0036), TGs (p=0.01), LDL-C (p=0.006), LDL-3 subfraction (p= 0.08) and VLDL (p=0.03)]
Conclusion: A modest relationship between a higher omega-3 index and a less atherogenic lipoprotein profile was observed at the time of MI, 
but there was no association with inflammatory status. After adjustment for potential confounding patient characteristics, none of the lipid profile 
parameters explained more than 11% of the variability in omega-3 index. This suggests that the benefits of higher omega-3 levels on outcomes are 
probably not mediated by effects on lipids.
